首页> 外文期刊>Journal of Clinical Pathology >BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
【24h】

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.

机译:在各种内部器官中产生的黑色素瘤中,BRAF和NRAS突变并不常见。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas. AIMS: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs. METHODS: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing. RESULTS: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas. CONCLUSION: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.
机译:背景:来自不同体腔的恶性黑色素瘤可能与不同的病因和临床行为有关,并可能表现出多种分子遗传学特征。尽管许多研究都集中在皮肤黑色素瘤上,但对于粘膜和其他类型的黑色素瘤知之甚少。特别地,软部分的恶性黑色素瘤在许多方面与其他黑色素瘤不同,但表现出常见的黑素细胞分化。现在已知BRAF的突变在皮肤黑素瘤中很常见,并且为这些患者带来了抗RAF治疗的新治疗选择。非皮肤黑色素瘤的数据很少。目的:研究BRAF和NRAS突变在各种内部器官中产生的黑色素瘤的发生率。方法:通过直接DNA测序研究了51个来自各个内部器官的黑色素瘤的BRAF和NRAS突变。结果:在两个和五个粘膜黑色素瘤中发现了BRAF和NRAS突变,这是由消化道和女性生殖道引起的(n = 36)。它们的发生是互斥的,在粘膜黑色素瘤中的合并突变发生率为19.4%。在软性部分的恶性黑色素瘤中,BRAF和NRAS突变均不存在(n = 7)。在葡萄膜黑色素瘤中也没有BRAF突变(n = 6),但在五个皮肤黑色素瘤中有两个见到。在所有非皮肤组中,BRAF或BRAF / NRAS组合突变的发生率均明显低于已公布的皮肤黑色素瘤发生率。结论:每种黑色素瘤亚型都可能具有独特的肿瘤发生癌发生途径,只有一小部分非皮肤黑色素瘤可以从抗RAF治疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号